title: The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics.
abstract: Many types of human cancer are characterized by deregulation of the human epidermal growth factor receptor (HER) family of tyrosine kinase receptors. In some cancers, genomic events causing overactivity of individual HER family members are etiologically linked with the pathogenesis of these cancers, and constitute the driving signaling function underlying their tumorigenic behavior. HER3 stands out among this family as the only member lacking catalytic kinase function. Cancers with driving HER3 amplifications or mutations have not been found, and studies of its expression in tumors have been only weakly provocative. However, substantial evidence, predominantly from experimental models, now suggest that its non-catalytic functions are critically important in many cancers driven by its' HER family partners. Furthermore, new insights into the mechanism of activation in the HER family has provided clear evidence of functionality in the HER3 kinase domain. The convergence of structural, mechanistic, and experimental evidence highlighting HER3 functions that may be critical in tumorigenesis have now led to renewed efforts towards identification of cancers or subtypes of cancers wherein HER3 function may be important in tumor progression or drug resistance. It appears now that its failure to earn the traditional definition of an oncogene has allowed the tumor promoting functions of HER3 to elude the effects of cancer therapeutics. But experimental science has now unmasked the unpretentious role of HER3 in cancer biology, and the next generation of cancer therapies will undoubtedly perform much better because of it.
authors.affiliation: University of California, San Francisco, Medicine, San Francisco, CA 94143-1387, USA.
authors.forename: Dhara N
authors.initials: DN
authors.lastname: Amin
authors.forename: Marcia R
authors.initials: MR
authors.lastname: Campbell
authors.forename: Mark M
authors.initials: MM
authors.lastname: Moasser
mesh_terms: D019008:Drug Resistance, Neoplasm; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D020893:Receptor, ErbB-3 / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction
chemical_list: D020893:Receptor, ErbB-3
references.citation: J Biol Chem. 2000 Mar 24;275(12):8641-9
references.pmid: 10722704
references.citation: J Clin Oncol. 2006 Sep 10;24(26):4317-23
references.pmid: 16896008
references.citation: Ai Zheng. 2004 May;23(5):568-72
references.pmid: 15142456
references.citation: J Cancer Res Clin Oncol. 2000 Apr;126(4):205-11
references.pmid: 10782893
references.citation: Mol Cell Biol. 1994 Jun;14(6):3550-8
references.pmid: 7515147
references.citation: BMC Cancer. 2006 Feb 28;6:46
references.pmid: 16507107
references.citation: Int J Cancer. 2006 Jan 15;118(2):284-9
references.pmid: 16049961
references.citation: Science. 2007 May 18;316(5827):1039-43
references.pmid: 17463250
references.citation: J Clin Invest. 2006 Oct;116(10):2695-706
references.pmid: 16906227
references.citation: Ann Oncol. 2008 Jun;19(6):1068-74
references.pmid: 18283035
references.citation: Cancer Res. 2005 Sep 1;65(17):7591-5
references.pmid: 16140923
references.citation: Clin Mol Pathol. 1996 Aug;49(4):M199-202
references.pmid: 16696074
references.citation: Biochem Soc Trans. 2009 Feb;37(Pt 1):217-22
references.pmid: 19143635
references.citation: Lung Cancer. 2008 Nov;62(2):193-201
references.pmid: 18450321
references.citation: Ann Oncol. 2009 Jun;20(6):1026-31
references.pmid: 19179558
references.citation: Mol Syst Biol. 2005;1:2005.0008
references.pmid: 16729043
references.citation: Cancer Cell. 2010 Mar 16;17(3):298-310
references.pmid: 20227043
references.citation: Crit Rev Oncol Hematol. 2010 May;74(2):73-8
references.pmid: 19481955
references.citation: Int J Cancer. 1995 Jun 22;64(3):202-6
references.pmid: 7622309
references.citation: J Biol Chem. 1996 Feb 16;271(7):3884-90
references.pmid: 8632008
references.citation: Pigment Cell Melanoma Res. 2009 Dec;22(6):773-84
references.pmid: 19659570
references.citation: Cancer Cell. 2010 Jan 19;17(1):98-110
references.pmid: 20129251
references.citation: Sci Transl Med. 2010 Jan 27;2(16):16ra7
references.pmid: 20371474
references.citation: J Natl Cancer Inst. 2007 Apr 18;99(8):628-38
references.pmid: 17440164
references.citation: Biochem J. 1997 Mar 15;322 ( Pt 3):757-63
references.pmid: 9148746
references.citation: Clin Cancer Res. 2002 Dec;8(12):3933-42
references.pmid: 12473609
references.citation: Mol Cancer Ther. 2003 Oct;2(10):971-84
references.pmid: 14578462
references.citation: EMBO J. 1996 May 15;15(10):2452-67
references.pmid: 8665853
references.citation: Int J Cancer. 2003 Sep 20;106(5):758-65
references.pmid: 12866037
references.citation: Nature. 2006 Jan 12;439(7073):168-74
references.pmid: 16273093
references.citation: Melanoma Res. 2004 Jun;14(3):207-10
references.pmid: 15179190
references.citation: Lancet Oncol. 2009 Jun;10(6):581-8
references.pmid: 19394894
references.citation: Cancer Res. 2008 Jul 15;68(14):5878-87
references.pmid: 18632642
references.citation: Cell. 2006 Jun 16;125(6):1137-49
references.pmid: 16777603
references.citation: J Neuropathol Exp Neurol. 2006 Aug;65(8):769-75
references.pmid: 16896310
references.citation: J Biol Chem. 2005 Mar 4;280(9):8238-47
references.pmid: 15611073
references.citation: FEBS Lett. 2004 Jul 2;569(1-3):332-6
references.pmid: 15225657
references.citation: Nat Genet. 2009 Oct;41(10):1127-32
references.pmid: 19718025
references.citation: Br J Cancer. 1996 Jul;74(2):229-33
references.pmid: 8688326
references.citation: Clin Cancer Res. 2009 Jun 15;15(12):4147-56
references.pmid: 19509167
references.citation: Mol Cell Biol. 2007 Mar;27(6):2180-8
references.pmid: 17210635
references.citation: J Clin Invest. 2009 Sep;119(9):2702-13
references.pmid: 19690388
references.citation: Cancer Res. 2005 Dec 15;65(24):11478-85
references.pmid: 16357156
references.citation: Adv Cancer Res. 2005;94:29-86
references.pmid: 16095999
references.citation: Cancer Res. 2007 Feb 15;67(4):1645-52
references.pmid: 17308105
references.citation: Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8132-6
references.pmid: 8058768
references.citation: Int J Cancer. 2008 Jul 15;123(2):340-347
references.pmid: 18398842
references.citation: Mol Cell Biol. 1994 Jan;14(1):492-500
references.pmid: 8264617
references.citation: Dev Cell. 2007 Apr;12(4):487-502
references.pmid: 17419990
references.citation: Mod Pathol. 1997 Feb;10(2):142-8
references.pmid: 9127320
references.citation: Clin Cancer Res. 2000 Nov;6(11):4217-25
references.pmid: 11106235
references.citation: J Biol Chem. 2006 Jul 14;281(28):19310-9
references.pmid: 16690615
references.citation: Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7792-6
references.pmid: 1715580
references.citation: J Pathol. 1993 Jul;170(3):271-8
references.pmid: 8133400
references.citation: Proc Natl Acad Sci U S A. 2009 Dec 22;106(51):21608-13
references.pmid: 20007378
references.citation: Oncogene. 2008 Jun 19;27(27):3870-4
references.pmid: 18264138
references.citation: Mol Cell Biol. 1996 Oct;16(10):5276-87
references.pmid: 8816440
references.citation: Clin Cancer Res. 2005 Mar 15;11(6):2163-8
references.pmid: 15788662
references.citation: Clin Cancer Res. 2009 Aug 1;15(15):4829-37
references.pmid: 19622585
references.citation: J Clin Oncol. 2002 Feb 1;20(3):719-26
references.pmid: 11821453
references.citation: J Pathol. 2003 Jul;200(3):290-7
references.pmid: 12845624
references.citation: J Neuropathol Exp Neurol. 2007 Aug;66(8):740-9
references.pmid: 17882018
references.citation: Science. 2004 Jun 4;304(5676):1497-500
references.pmid: 15118125
references.citation: Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8933-8
references.pmid: 12853564
references.citation: Cancer Res. 2006 Dec 1;66(23):11279-86
references.pmid: 17145873
references.citation: Breast Cancer Res. 2008;10(1):R2
references.pmid: 18182100
references.citation: J Biol Chem. 2004 Nov 5;279(45):47050-6
references.pmid: 15345710
references.citation: Br J Cancer. 1998 Nov;78(10):1385-90
references.pmid: 9823984
references.citation: Chin Med Sci J. 1997 Jun;12(2):67-70
references.pmid: 11324501
references.citation: Int J Biochem Cell Biol. 2007;39(5):851-6
references.pmid: 17254832
references.citation: Semin Oncol. 1999 Aug;26(4 Suppl 12):78-83
references.pmid: 10482197
references.citation: Clin Cancer Res. 2009 May 15;15(10):3315-24
references.pmid: 19447869
references.citation: Nature. 2007 Jan 25;445(7126):437-41
references.pmid: 17206155
references.citation: Cancer Res. 2008 Oct 15;68(20):8286-94
references.pmid: 18922900
references.citation: Cancer Cell. 2010 Jan 19;17(1):77-88
references.pmid: 20129249
references.citation: Cancer Res. 2009 Mar 15;69(6):2195-200
references.pmid: 19276373
references.citation: Hum Pathol. 1998 Aug;29(8):771-7
references.pmid: 9712416
references.citation: PLoS Med. 2005 Mar;2(3):e73
references.pmid: 15737014
references.citation: N Engl J Med. 2004 May 20;350(21):2129-39
references.pmid: 15118073
references.citation: Clin Cancer Res. 2004 Oct 15;10(20):6779-88
references.pmid: 15501954
references.citation: Oncogene. 1989 Oct;4(10):1175-83
references.pmid: 2571965
references.citation: EMBO J. 1994 Jun 15;13(12):2831-41
references.pmid: 8026468
references.citation: Int J Cancer. 2006 Dec 15;119(12):2986-7
references.pmid: 16998794
references.citation: Glia. 2005 Aug 15;51(3):217-28
references.pmid: 15812817
references.citation: Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3788-93
references.pmid: 15731348
references.citation: Br J Cancer. 1995 Apr;71(4):758-62
references.pmid: 7710941
references.citation: J Clin Oncol. 1999 Sep;17(9):2639-48
references.pmid: 10561337
references.citation: Clin Cancer Res. 2008 Aug 15;14(16):5188-97
references.pmid: 18698037
references.citation: Int J Cancer. 2009 Dec 1;125(11):2565-75
references.pmid: 19530240